NURIX THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
NURIX THERAPEUTICS, INC. (NRIX) reported Increase Decrease In Operating Lease Liability of -$352.00 thousand for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-05-31 was -$557.00K.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-02-28 was $205.00K.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-11-30 was -$756.00K.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-08-31 was -$1.23M.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$5.07M.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$6.42M.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$6.27M.
- NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$4.87M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$557.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$352.00K 10-Q · filed 2026-07-09 | -$1.11M derived: sum of 3 quarters · filed 2026-07-09 | -$2.34M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $205.00K 10-Q · filed 2026-04-08 | -$551.00K derived: sum of 2 quarters · filed 2026-04-08 | -$1.78M derived: sum of 3 quarters · filed 2026-04-08 | -$3.18M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | -$756.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$1.99M derived: sum of 2 quarters · filed 2026-01-28 | -$3.39M derived: sum of 3 quarters · filed 2026-07-09 | -$5.07M 10-K · filed 2026-01-28 |
| 2025-08-31 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$2.63M derived: sum of 2 quarters · filed 2026-07-09 | -$4.31M 10-Q · filed 2025-10-09 | -$5.96M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$3.08M 10-Q · filed 2026-07-09 | -$4.73M derived: sum of 3 quarters · filed 2026-07-09 | -$6.41M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | -$1.68M 10-Q · filed 2026-04-08 | -$3.33M derived: sum of 2 quarters · filed 2026-04-08 | -$5.01M derived: sum of 3 quarters · filed 2026-04-08 | -$6.64M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$3.33M derived: sum of 2 quarters · filed 2026-01-28 | -$4.96M derived: sum of 3 quarters · filed 2026-01-28 | -$6.42M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$3.31M derived: sum of 2 quarters · filed 2025-10-09 | -$4.77M 10-Q · filed 2025-10-09 | -$6.10M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | -$3.09M 10-Q · filed 2025-07-09 | -$4.42M derived: sum of 3 quarters · filed 2026-01-28 | -$6.28M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$1.46M 10-Q · filed 2025-04-08 | -$2.79M derived: sum of 2 quarters · filed 2026-01-28 | -$4.64M derived: sum of 3 quarters · filed 2026-01-28 | -$6.42M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$3.18M derived: sum of 2 quarters · filed 2026-01-28 | -$4.97M derived: sum of 3 quarters · filed 2026-01-28 | -$6.27M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | -$3.64M derived: sum of 2 quarters · filed 2024-10-11 | -$4.94M 10-Q · filed 2024-10-11 | -$6.13M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | -$3.08M 10-Q · filed 2024-07-11 | -$4.28M derived: sum of 3 quarters · filed 2025-01-28 | -$5.41M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | -$1.30M 10-Q · filed 2024-04-10 | -$2.49M derived: sum of 2 quarters · filed 2025-01-28 | -$3.63M derived: sum of 3 quarters · filed 2025-01-28 | -$5.76M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$2.32M derived: sum of 2 quarters · filed 2025-01-28 | -$4.46M derived: sum of 3 quarters · filed 2025-01-28 | -$4.87M 10-K · filed 2025-01-28 |
| 2022-08-31 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | -$3.27M derived: sum of 2 quarters · filed 2023-10-12 | -$3.68M 10-Q · filed 2023-10-12 | -$6.39M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | -$2.55M 10-Q · filed 2023-07-13 | -$5.26M derived: sum of 3 quarters · filed 2023-07-13 | -$6.14M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | -$408.00K 10-Q · filed 2023-04-13 | -$3.12M derived: sum of 2 quarters · filed 2023-04-13 | -$4.00M derived: sum of 3 quarters · filed 2023-04-13 | -$4.82M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | -$2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$3.59M derived: sum of 2 quarters · filed 2023-02-09 | -$4.41M derived: sum of 3 quarters · filed 2023-02-09 | -$5.14M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$877.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$1.70M derived: sum of 2 quarters · filed 2022-10-06 | -$2.43M 10-Q · filed 2022-10-06 | |
| 2021-05-31 | -$818.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | -$1.55M 10-Q · filed 2022-07-07 | ||
| 2021-02-28 | -$737.00K 10-Q · filed 2022-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |